A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC).

ABSTRACT:

Background

Non-small cell lung cancer (NSCLC) imposes a substantial burden on patients, health care systems and society due to increasing incidence and poor survival rates. In recent years, advances in the treatment of metastatic NSCLC have resulted from the introduction of targeted therapies. However, the application of these new agents increases treatment costs considerably. The objective of this article is to review the economic evidence of targeted therapies in metastatic NSCLC.

Methods

A systematic literature review was conducted to identify cost-effectiveness (CE) as well as cost-utility studies. Medline, Embase, SciSearch, Cochrane, and 9 other databases were searched from 2000 through April 2013 (including update) for full-text publications. The quality of the studie

SUBMITTER: Lange A 

PROVIDER: S-EPMC4269853 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature